Athenex (ATNXQ) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	ATNX
Entity Registrant Name	Athenex, Inc.
Entity Central Index Key	0001300699
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		77,505,885
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38112
Entity Tax Identification Number	43-1985966
Entity Address, Address Line One	1001 Main Street
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Buffalo
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14203
City Area Code	716
Local Phone Number	427-2950
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 61,481	$ 49,794
Restricted cash	25,424
Short-term investments	42,273	57,629
Accounts receivable, net of chargebacks and other deductions of $19,909 and $13,101, respectively, and allowance for doubtful accounts of $133 and $9, respectively	17,168	12,951
Inventories	28,451	28,787
Prepaid expenses and other current assets	38,744	21,658
Total current assets	213,541	170,819
Property and equipment, net	19,272	11,447
Goodwill	37,293	37,495
Intangible assets, net	8,972	10,848
Operating lease right-of-use assets, net	8,517
Deferred income tax assets		486
Total assets	287,595	231,095
Current liabilities:
Accounts payable	16,206	12,997
Accrued expenses	69,994	37,718
Current portion of operating lease liabilities	2,810
Current portion of long-term debt	958	961
Total current liabilities	89,968	51,676
Long-term liabilities:
Deferred compensation	2,541	2,825
Deferred rent		2,022
Long-term operating lease liabilities	7,579
Long-term debt and finance lease obligations	52,681	45,803
Total liabilities	152,769	102,326
Commitments and contingencies (See Note 16)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at September 30, 2019 and December 31, 2018; 79,142,305 and 68,668,986 shares issued at September 30, 2019 and December 31, 2018, respectively; 77,469,385 and 66,996,066 shares outstanding at September 30, 2019 and December 31, 2018, respectively	79	69
Additional paid-in capital	700,000	591,064
Accumulated other comprehensive loss	(423)	(656)
Accumulated deficit	(545,738)	(443,716)
Less: treasury stock, at cost; 1,672,920 shares at September 30, 2019 and December 31, 2018	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	146,512	139,355
Non-controlling interests	(11,686)	(10,586)
Total stockholders' equity	134,826	128,769
Total liabilities and stockholders' equity	$ 287,595	$ 231,095

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks and other deductions (in dollars)	$ 19,909	$ 13,101
Allowance for doubtful accounts (in dollars)	$ 133	$ 9
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	79,142,305	68,668,986
Common Stock, shares outstanding	77,469,385	66,996,066
Treasury stock, shares	1,672,920	1,672,920

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Total revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
Costs and operating expenses:
Cost of sales	17,071	11,965	53,915	32,734
Research and development expenses	19,588	51,202	62,570	99,077
Selling, general, and administrative expenses	16,283	11,493	48,640	37,390
Total costs and operating expenses	52,942	74,660	165,125	169,201
Operating loss	(33,578)	(56,232)	(98,257)	(101,372)
Interest income	(650)	(654)	(1,408)	(1,314)
Interest expense	1,745	1,712	5,254	1,777
Loss before income tax expense (benefit)	(34,673)	(57,290)	(102,103)	(101,835)
Income tax expense (benefit)	114	(30)	1,019	(286)
Net loss	(34,787)	(57,260)	(103,122)	(101,549)
Less: net loss attributable to non-controlling interests	(29)	(11,090)	(1,100)	(11,222)
Net loss attributable to Athenex, Inc.	(34,758)	(46,170)	(102,022)	(90,327)
Unrealized gain (loss) on investment, net of income taxes	1	(37)	(79)	3
Foreign currency translation adjustment, net of income taxes	(310)	(554)	312	(477)
Comprehensive loss	$ (35,067)	$ (46,761)	$ (101,789)	$ (90,801)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 13)	$ (0.45)	$ (0.70)	$ (1.41)	$ (1.42)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 13)	77,297,555	66,399,091	72,552,248	63,806,787
Product Sales, Net
Revenue:
Total revenue	$ 19,237	$ 13,309	$ 66,433	$ 37,385
License Fees and Consulting Revenue
Revenue:
Total revenue	115	5,096	325	30,278
Grant Revenue
Revenue:
Total revenue	$ 12	$ 23	$ 110	$ 166

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning balance at Dec. 31, 2017	$ 90,722	$ 60	$ 423,805	$ (326,276)	$ (146)	$ (7,406)	$ 90,037	$ 685
Beginning balance, shares at Dec. 31, 2017		59,894,362				(1,672,920)
Sale of common stock	68,055	$ 4	68,051				68,055
Sale of common stock, shares		4,765,000
Stock-based compensation cost	2,161		2,161				2,161
Restricted stock expense	540		540				540
Stock options and warrants exercised	1,263	$ 1	1,262				1,263
Stock options and warrants exercised, shares		289,487
Net loss	(7,339)			(7,298)			(7,298)	(41)
Other comprehensive income (loss), net of tax	683				683		683
Ending balance at Mar. 31, 2018	156,085	$ 65	495,819	(333,574)	537	$ (7,406)	155,441	644
Ending balance, shares at Mar. 31, 2018		64,948,849				(1,672,920)
Beginning balance at Dec. 31, 2017	90,722	$ 60	423,805	(326,276)	(146)	$ (7,406)	90,037	685
Beginning balance, shares at Dec. 31, 2017		59,894,362				(1,672,920)
Net loss	(101,549)
Ending balance at Sep. 30, 2018	152,057	$ 68	587,155	(416,603)	(620)	$ (7,406)	162,594	(10,537)
Ending balance, shares at Sep. 30, 2018		68,561,678				(1,672,920)
Beginning balance at Mar. 31, 2018	156,085	$ 65	495,819	(333,574)	537	$ (7,406)	155,441	644
Beginning balance, shares at Mar. 31, 2018		64,948,849				(1,672,920)
Stock-based compensation cost	3,081		3,081				3,081
Vesting of restricted stock	462		462				462
Vesting of restricted stock, shares		210,000
Stock options and warrants exercised	296		296				296
Stock options and warrants exercised, shares		27,630
Research and development licensing fee satisfied with stock	2,000		2,000				2,000
Research and development licensing fee satisfied with stock, shares		107,181
Net loss	(36,950)			(36,859)			(36,859)	(91)
Other comprehensive income (loss), net of tax	(566)				(566)		(566)
Ending balance at Jun. 30, 2018	124,408	$ 65	501,658	(370,433)	(29)	$ (7,406)	123,855	553
Ending balance, shares at Jun. 30, 2018		65,293,660				(1,672,920)
Sale of common stock	49,093	$ 3	49,090				49,093
Sale of common stock, shares		2,679,528
Issuance of warrants	3,140		3,140				3,140
Stock-based compensation cost	2,316		2,316				2,316
Vesting of restricted stock	5		5				5
Vesting of restricted stock, shares		30,000
Stock options and warrants exercised	1,401		1,401				1,401
Stock options and warrants exercised, shares		290,538
Research and development licensing fee satisfied with stock	29,545		29,545				29,545
Research and development licensing fee satisfied with stock, shares		267,952
Net loss	(57,260)			(46,170)			(46,170)	(11,090)
Other comprehensive income (loss), net of tax	(591)				(591)		(591)
Ending balance at Sep. 30, 2018	152,057	$ 68	587,155	(416,603)	(620)	$ (7,406)	162,594	(10,537)
Ending balance, shares at Sep. 30, 2018		68,561,678				(1,672,920)
Beginning balance at Dec. 31, 2018	128,769	$ 69	591,064	(443,716)	(656)	$ (7,406)	139,355	(10,586)
Beginning balance, shares at Dec. 31, 2018		68,668,986				(1,672,920)
Stock-based compensation cost	1,693		1,693				1,693
Stock options exercised	278		278				278
Stock options exercised, shares		49,632
Net loss	(36,230)			(35,233)			(35,233)	(997)
Other comprehensive income (loss), net of tax	1,071				1,071		1,071
Ending balance at Mar. 31, 2019	95,581	$ 69	593,035	(478,949)	415	$ (7,406)	107,164	(11,583)
Ending balance, shares at Mar. 31, 2019		68,718,618				(1,672,920)
Beginning balance at Dec. 31, 2018	$ 128,769	$ 69	591,064	(443,716)	(656)	$ (7,406)	139,355	(10,586)
Beginning balance, shares at Dec. 31, 2018		68,668,986				(1,672,920)
Stock options exercised, shares	217,234
Net loss	$ (103,122)
Ending balance at Sep. 30, 2019	134,826	$ 79	700,000	(545,738)	(423)	$ (7,406)	146,512	(11,686)
Ending balance, shares at Sep. 30, 2019		79,142,305				(1,672,920)
Beginning balance at Mar. 31, 2019	95,581	$ 69	593,035	(478,949)	415	$ (7,406)	107,164	(11,583)
Beginning balance, shares at Mar. 31, 2019		68,718,618				(1,672,920)
Sale of common stock	100,319	$ 10	100,309				100,319
Sale of common stock, shares		10,033,362
Stock-based compensation cost	3,382		3,382				3,382
Stock-based compensation cost, shares		92,723
Stock options exercised	559		559				559
Stock options exercised, shares		92,442
Net loss	(32,105)			(32,031)			(32,031)	(74)
Other comprehensive income (loss), net of tax	(529)				(529)		(529)
Ending balance at Jun. 30, 2019	167,207	$ 79	697,285	(510,980)	(114)	$ (7,406)	178,864	(11,657)
Ending balance, shares at Jun. 30, 2019		78,937,145				(1,672,920)
Stock-based compensation cost	2,148		2,148				2,148
Stock-based compensation cost, shares		130,000
Stock options exercised	567		567				567
Stock options exercised, shares		75,160
Net loss	(34,787)			(34,758)			(34,758)	(29)
Other comprehensive income (loss), net of tax	(309)				(309)		(309)
Ending balance at Sep. 30, 2019	$ 134,826	$ 79	$ 700,000	$ (545,738)	$ (423)	$ (7,406)	$ 146,512	$ (11,686)
Ending balance, shares at Sep. 30, 2019		79,142,305				(1,672,920)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Sep. 30, 2018	Mar. 31, 2018
Statement Of Stockholders Equity [Abstract]
Stock issuance costs and discounts	$ 54	$ 907	$ 4,611

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (103,122)	$ (101,549)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,808	2,424
Stock-based compensation expense	7,223	8,659
Amortization of debt discount	770	256
Deferred rent expense		329
Loss (gain) on disposal of assets and impairment charges	224	(62)
Research and development license fees settled with convertible bond and stock		31,545
Deferred income taxes	486	(316)
Changes in operating assets and liabilities:
Receivables, net	(4,217)	1,397
Prepaid expenses and other assets	(17,086)	(6,290)
Inventories	336	(8,670)
Accounts payable and accrued expenses	38,458	(3,038)
Net cash used in operating activities	(74,120)	(75,315)
Cash flows from investing activities:
Purchase of property and equipment	(8,513)	(2,501)
Payments for licenses	(4,175)
Purchases of short-term investments	(57,014)	(110,605)
Sales and maturities of short-term investments	72,290	31,981
Net cash provided by (used in) investing activities	2,588	(81,125)
Cash flows from financing activities:
Proceeds from sale of stock	100,373	122,666
Proceeds from issuance of debt	6,464	50,000
Costs incurred related to the sale of stock	(54)	(5,118)
Costs incurred related to the issuance of debt		(1,593)
Proceeds from exercise of stock options	1,404	2,960
Repayment of finance lease obligations and long-term debt	(136)	(551)
Net cash provided by financing activities	108,051	168,364
Net increase in cash, cash equivalents, and restricted cash	36,519	11,924
Cash, cash equivalents, and restricted cash, beginning of period	49,794	39,284
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	592	(100)
Cash, cash equivalents, and restricted cash, end of period (See Note 3)	86,905	51,108
Supplemental cash flow disclosures
Interest paid	4,415	952
Non-cash investing and financing activities:
Accrued purchases of property and equipment	1,106	445
Cost of equity raise in accounts payable and accrued expenses		400
Common stock issued in lieu of licensing cash payment		$ 31,545
Right-of-use assets recognized in exchange for new operating lease obligations	$ 583

Company and Nature of Business

Company and Nature of Business	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Company and Nature of Business Organization and Description of Business Athenex, Inc. and subsidiaries (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company’s current clinical pipeline is derived from Orascovery, Src Kinase Inhibition, T-cell receptor-engineered T-cells (“TCR-T”), and Arginine Deprivation Therapy research platforms. The Company has assembled a leadership team and has established global operations across the pharmaceutical value chain to execute its mission to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The Company is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. The Company also conducts commercial sales of specialty products through its wholly owned subsidiary, Athenex Pharmaceutical Division (“APD”), and 503B products through its wholly-owned subsidiary, Athenex Pharma Solutions (“APS”). Follow-On Offering In January 2018, the Company completed an underwritten public offering of 4,300,000 shares of its common stock. The Company granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock. In February 2018, the underwriters partially exercised their option, purchasing an additional 465,000 shares of common stock. All shares were offered by the Company at a price of $15.25 per share. The aggregate net proceeds were $68.1 million, net of underwriting discounts and commissions and offering expenses of $4.6 million. Debt and Equity Offering On July 3, 2018, the Company closed a privately placed debt and equity financing deal with Perceptive Advisors LLC and its affiliates (“Perceptive”) for gross proceeds of $100.0 million and received aggregate net proceeds of $97.1 million, net of fees and offering expenses. The Company entered into a 5-year senior secured loan for $50.0 million of this financing and issued 2,679,528 shares of its common stock at a purchase price of $18.66 per share for the remaining $50.0 million. The loan matures on the fifth anniversary from the closing date and bears interest at a floating per annum rate equal to London Interbank Offering Rates (“LIBOR”) (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. The loan agreement contains specified financial maintenance covenants. In connection with the loan agreement, the Company granted Perceptive a warrant for the purchase of 425,000 shares of common stock at a purchase price of $18.66 per share. This was accounted for as a detachable warrant at its fair value and is recorded as an increase to additional paid-in-capital on the condensed consolidated statement of stockholders’ equity. Private Placement On May 7, 2019, the Company closed a private placement with Perceptive Life Sciences Master Fund, Ltd., Avoro Capital Advisors (formerly known as venBio Select Fund LLC), OrbiMed Partners Master Fund Limited and the Biotech Growth Trust PLC (combined known as OrbiMed), (collectively, the “Investors”), pursuant to which the Company sold an aggregate of 10 million shares of its common stock to the Investors at a purchase price of $10.00 per share for aggregate net proceeds of $99.9 million, net of offering expenses of approximately $0.1 million. Significant Risks and Uncertainties The Company has incurred operating losses since its inception and, as a result, as of September 30, 2019 and December 31, 2018 had an accumulated deficit of $545.7 million and $443.7 million, respectively. As of September 30, 2019, the Company had $129.2 These condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company has a senior secured loan agreement with Perceptive which contains various covenants. A breach of any of these covenants could result in a default. If a default under this loan agreement is not cured or waived, the default could result in the acceleration of debt, which could require the Company to repurchase or repay the debt in full prior to the date it is otherwise due. If the Company defaults, the lender may seek repayment through the Company’s subsidiary guarantors or by executing on the security interest granted pursuant to the loan agreement. The Company is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, unsuccessful commercialization strategy and launch plans for its proprietary drug candidates, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate sufficient product revenue and might not, if ever, achieve profitability and positive cash flow.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, do not include all of the information the opinion of management, reflect all normal recurring adjustments necessary a fair of the results for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been eliminated Results of the Company’s operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results expected for the year ending December 31, 2019, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, allowance for doubtful accounts, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates. Leases On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the contractual terms of the operating leases. The Company uses its incremental borrowing rate based on the information available at the date of initial adoption in determining the present value of the future lease payments. The Company uses the stated rate per each lease agreement in determining the finance lease liabilities. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. The lease liabilities and ROU asset are amortized over the term of the lease with operating lease expenses being recognized on a straight-line basis over the lease terms. The Company elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term leases. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, " Leases (Topic 842), The Company adopted the new lease standard on January 1, 2019 and used the effective date as the date of initial application. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company also elected the single component practical expedient, which requires the Company, by class of underlying asset, not to allocate the total consideration to the lease and nonlease components based on their relative stand-alone selling prices. This single component practical expedient requires the Company to account for the lease component and nonlease component(s) associated with that lease as a single component if (i) the timing and pattern of transfer of the lease component and the nonlease component(s) associated with it are the same and (ii) the lease component would be classified as an operating lease if it were accounted for separately. In preparation for adoption of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard had a material impact on the consolidated balance sheet, with no material impact on its consolidated statement of operations and comprehensive loss. On the adoption date, the Company recognized $9.8 million of operating lease ROU assets, $11.9 million of operating lease liabilities, and derecognized its existing deferred rent balance of $2.1 million. In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation – Stock Compensation Recently Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Measurement of Credit Losses on Financial Instruments”

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2019
Restricted Cash [Abstract]
Restricted Cash	3. Restricted Cash The Company’s restricted cash balance of $25.4 million as of September 30, 2019 consisted of $25.0 million of secured deposits held in a designated bank account for the issuance of an irrevocable standby letter of credit with an expiration date of December 15, 2019 related to a milestone payment arrangement pursuant to the license agreement between the Company and Almirall S.A. (“Almirall”), and $0.4 million of restricted cash deposits as security.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of the following (in thousands): September 30, 2019 December 31, 2018 Raw materials and purchased parts $ 3,597 $ 4,092 Work in progress 2,012 3,166 Finished goods 22,842 21,529 Total inventories $ 28,451 $ 28,787

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, net	5. Intangible Assets, net The Company’s identifiable intangible assets, net, consist of the following (in thousands): September 30, 2019 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 8,935 $ 3,184 $ — $ 5,751 Polymed customer list 1,593 1,101 — 492 Polymed technology 3,712 1,194 — 2,518 Product rights 525 360 165 — Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 715 — — 715 Effect of currency translation adjustment (504 ) — — (504 ) Total intangible assets, net $ 14,976 $ 5,839 $ 165 $ 8,972 December 31, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 2,060 $ — $ 6,875 Polymed customer list 1,593 938 — 655 Polymed technology 3,712 999 — 2,713 Product rights 530 263 — 267 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — 298 728 Effect of currency translation adjustment (390 ) — — (390 ) Total intangibles, net $ 15,406 $ 4,260 $ 298 $ 10,848 As of September 30, 2019, licenses at cost include an Orascovery license of $0.4 million, licenses purchased from Gland Pharma Limited (“Gland”) of $4.3 million, and a license purchased from MAIA Pharmaceuticals, Inc. (“MAIA”) for $4.0 million. The Orascovery license with Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) was purchased directly from Hanmi and is being amortized on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The licenses purchased from Gland are being amortized on a straight-line basis over a period of 5 years, the remaining life of the license agreement at the time of purchase. The license purchased from MAIA is being amortized over a period of 7 years, the remaining life of the license agreement at the time of purchase. The remaining intangible assets were acquired in connection with the acquisitions of APS (formerly known as QuaDPharma), Polymed Therapeutics, Inc. (“Polymed”), and Comprehensive Drug Enterprises (“CDE”). Intangible assets are amortized using an economic consumption model over their useful lives. The APS customer list is being amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, (“IPR&D”), will not be amortized until the related projects are completed. IPR&D will be tested annually for impairment, unless conditions exist causing an earlier impairment test (e.g., abandonment of project). During the three months ended September 30, 2019, the Company determined that its product rights, initially acquired as IPR&D in connection with the acquisition of CDE, was impaired due to a lack of historical and forecasted sales and therefore, the related balance of $0.2 million was written-off as impaired and is included within research and development expenses in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2019. The weighted-average useful life for all intangible assets was 7.7 years as of September 30, 2019. The Company recorded $0.5

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments and the equity investment are stated at fair value. Cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements , establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows: Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at September 30, 2019 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 32 $ 32 $ — $ — Short-term investments - commercial paper 21,164 — 21,164 — Financial assets included within short-term investments Short-term investments - certificates of deposit 10,000 — 10,000 — Short-term investments - commercial paper 32,022 — 32,022 — Available-for-sale investment 251 251 — — Total assets $ 63,469 $ 283 $ 63,186 $ — Fair Value Measurements at December 31, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 25 $ 25 $ — $ — Short-term investments - commercial paper 5,396 — 5,396 — Financial assets included within short-term investments Short-term investments - commercial paper 36,544 — 36,544 — Short-term investments - corporate notes 16,699 — 16,699 — Short-term investments - U.S. government bonds 3,998 — 3,998 — Available-for-sale investment 388 388 — — Total assets $ 63,050 $ 413 $ 62,637 $ — The Company classifies its money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, certificates of deposit, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all Level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange. As of September 30, 2019 and December 31, 2018, the Company’s investment in PharmaEssentia was valued at the reported closing price on such dates. This investment is classified as a Level 1 investment and is recorded as an available-for-sale investment within short-term investments on the Company’s condensed consolidated balance sheet.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2019
Asset Acquisition [Abstract]
Acquisitions	7. Acquisitions CIDAL On June 27, 2019, the Company entered into a definitive asset purchase agreement (“the APA”) with CIDAL Limited, a British Virgin Islands company limited by shares, and several of its affiliates (“CIDAL”). CIDAL operates as a contract research organization with headquarters in Guatemala and operations in various countries in Latin America. Pursuant to the terms of the APA, the Company acquired certain assets of CIDAL in exchange for agreeing to assume certain liabilities of CIDAL, and subject to certain contingencies and post-closing purchase price adjustments, issuing shares of the Company’s common stock to CIDAL. Under the terms of the APA, the Company also agreed to milestone payments of up to an aggregate of 67,796 shares of the Company’s common stock upon the achievement of certain developmental and regulatory milestones through the third quarter of 2021. The transactions contemplated by the asset purchase agreement closed on October 31, 2019. We believe the acquisition strategically strengthens the Company’s clinical research and operations capabilities and further supports its clinical development worldwide. The Company accounted for the asset purchase using the acquisition method of accounting and accordingly, the identifiable assets acquired, and liabilities assumed were recorded based upon management’s estimates of current fair values as of the acquisition date. The purchase price amounted to approximately $2.2 million, consisting of approximately $1.1 million of liabilities assumed and approximately $1.1 million of contingent consideration. The Company received net cash of $0.8 million, acquired fixed assets of less than $0.1 million, and recorded goodwill of approximately $1.4 million. AXIS On June 29, 2018, the Company entered into a Share Subscription Agreement (“SSA”) for Axis Therapeutics Limited (“Axis”), a subsidiary of the Company jointly owned by the Company and Xiangxue Life Sciences Limited (“XLifeSc”). Under the SSA, the Company contributed $30.0 million cash for a 55% ownership interest in Axis and XLifeSc contributed a license for The Company has consolidated the financial statements of Axis into its condensed consolidated financial statements as of and for the nine months ended September 30, 2019

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2019
Payables And Accruals [Abstract]
Accrued Expenses	8. Accrued Expenses Accrued expenses consist of the following (in thousands): September 30, December 31, 2019 2018 Accrued wages and benefits $ 6,277 $ 5,061 Accrued clinical expenses 2,848 2,653 Accrued operating expenses 5,994 8,128 Deferred revenue 20,071 190 Accrued R&D licensing fees 382 4,827 Accrued tax withholdings 256 — Accrued selling fees and rebates 1,436 423 Accrued construction costs 32,730 16,436 Total accrued expenses $ 69,994 $ 37,718 The accrued construction costs relate to the building of the manufacturing facility in Dunkirk, NY. Of this amount, the Company expects $32.1 million to be reimbursed by New York State. This amount is recorded within prepaid expenses and other current assets on the Company’s condensed consolidated balance sheet as of September 30, 2019 Revenue Recognition

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company did not record a provision for federal income taxes for the nine months ended September 30, 2019 because it expects to generate a loss for the year ending December 31, 2019 and the Company’s net deferred tax assets continue to be fully offset by a valuation allowance.

Debt and Lease Obligations

Debt and Lease Obligations	9 Months Ended
	Sep. 30, 2019
Debt And Lease Obligations [Abstract]
Debt and Lease Obligations	10. Debt and Lease Obligations Debt The Company’s debt as of September 30, 2019 and December 31, 2018, consists of the following (in thousands): September 30, December 31, 2019 2018 Current portion of mortgage $ 70 $ 779 Current portion of bank loan 697 — Current portion of finance and capital lease obligations 191 182 Current portion of operating lease obligations 2,810 — Long-term portion of finance and capital lease obligations 277 422 Long-term portion of operating lease obligations 7,579 — Long-term portion of mortgage 670 — Chongqing Maliu Credit Agreement 5,583 — Senior secured loan, net of debt discount and financing fees of $3,849 and $4,619, respectively 46,151 45,381 Total $ 64,028 $ 46,764 The mortgage payments, assumed in connection with the acquisition of CDE, extend through December 31, 2020. During 2018, Perceptive issued a senior secured loan to the Company with a principal value of $50.0 million and a maturity date of June 30, 2023. The loan bears interest at a floating per annum rate equal to LIBOR (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. During the first quarter of 2019, the Company was issued an unsecured, subordinated bank loan from China Merchants Bank to fund operations in China. This loan has a principal value of $0.7 million, a maturity date of December 11, 2019, and bears interest at a fixed rate of 5.7% annually. During the second quarter of 2019, the Company entered into a credit agreement which amended the existing partnership agreement with Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”), for a Renminbi ¥50.0 million line of credit to be used for the construction of the new active pharmaceutical ingredient (“API”) plant in China. The Company is required to repay the principal amount with accrued interest within three years after the plant receives the U.S. Current Good Manufacturing Practices (“cGMP”) certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months. Interest accrues at the three-year loan interest rate by the People’s Bank of China for the same period on the date of the deposit of the full loan amount. As of September 30, 2019, the balance due to CQ was $5.6 million. Lease Obligations The Company has operating leases for office and manufacturing facilities in several locations in the U.S. and Asia and has three finance leases for manufacturing equipment used in its facilities near Buffalo, NY. The components of lease expense are as follows (in thousands): Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 793 $ 2,365 Finance lease cost: Amortization of assets 21 46 Interest on lease liabilities 7 24 Total net lease cost $ 821 $ 2,435 The Company has elected to exclude short-term leases from its operating lease ROU assets and lease liabilities. Lease costs for short-term leases were not material to the financial statements for the three months ended September 30, 2019. Variable lease costs for the three and nine months ended September 30, 2019 were not material to the financial statements. Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): September 30, 2019 Operating leases: Operating lease ROU assets, net $ 8,517 Current operating lease liabilities $ 2,810 Long-term operating lease liabilities 7,579 Total operating lease liabilities $ 10,389 Finance leases: Property and equipment, at cost $ 660 Accumulated amortization, net (46 ) Property and equipment, net $ 614 Current obligations of finance leases $ 191 Long-term portion of finance leases 277 Total finance lease obligations $ 468 Weighted average remaining lease term (in years): Operating leases 5.54 Finance leases 2.36 Weighted average discount rate: Operating leases 13.0 % Finance leases 5.9 % Supplemental cash flow information related to leases is as follows (in thousands): Nine Months Ended September 30, 2019 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ 2,515 Operating cash flows from finance leases 24 Financing cash flows from finance leases 136 ROU assets recognized in exchange for new operating lease obligations $ 583 Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2019 (remaining three months) $ 823 $ 54 2020 2,941 214 2021 2,534 214 2022 2,354 21 2023 2,095 — Thereafter 3,952 — Total lease payments 14,699 503 Less: Imputed interest (4,310 ) (35 ) Total lease obligations 10,389 468 Less: Current obligations (2,810 ) (191 ) Long-term lease obligations $ 7,579 $ 277

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions During the nine months ended September 30, 2019 and 2018, the Company entered into transactions with individuals and companies that have financial interests in the Company. Related party transactions included the following: a. In 2015, CDE signed an agreement with Avalon BioMedical (Management) Limited and its subsidiaries (“Avalon”) under which Avalon would receive certain administrative services and would occupy space at CDE’s research location. Avalon would reimburse CDE for these administrative services as incurred and pay CDE a percentage of the total rent payment based on its staff headcount occupying the Hong Kong research and development facility (See Note 16— Commitments and Contingencies In June 2018, the Company entered into two in-licensing agreements with Avalon wherein the Company obtained certain intellectual property (“IP”) from Avalon to develop and commercialize the underlying products. Under these agreements the Company is required to pay upfront fees and future milestone payments and sales-based royalties. During the nine months ended September 30, 2018, the Company recorded $5.5 million of upfront fees, consisting of $3.5 million in cash and $2.0 million in equity, as research and development expenses on its condensed consolidated statement of operations and comprehensive loss. There were no fees paid during the three months ended September 30, 2018. During the three and nine months ended September 30, 2019, the Company recorded a $1.0 million milestone fee paid to Avalon, as research and development expenses on its condensed consolidated statement of operations and comprehensive loss. In June 2019, the Company entered into an agreement whereby Avalon will hold a 90% ownership interest and the Company will hold a 10% ownership interest of the newly formed entity under the name Nuwagen Limited (“Nuwagen”), incorporated under the laws of Hong Kong. Nuwagen is principally engaged in the development and commercialization of herbal medicine products for metabolic, endocrine, and other related indications. The Company will contribute nonmonetary assets in exchange for the 10% ownership interest. The Company will not consolidate Nuwagen under the voting model but will record its interest as an investment under the cost method. As of September 30, 2019, the Company had not yet recorded the investment since the transaction has not closed. b. The Company earns licensing revenue from PharmaEssentia, an entity in which the Company has an investment classified as available-for-sale (see Note 6— Fair Value Measurements c. The Company receives certain clinical development services from ZenRx Limited and its affiliate (“ZenRx”), a company for which one of the Company’s executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of d . Certain family members of executives perform consulting services for the Company. Such services were not significant to the condensed consolidated financial statements.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	12. Stock-Based Compensation Common Stock Option Plans The Company has four equity compensation plans, adopted in 2017, 2013, 2007 and 2004 (the “Plans”) which, taken together, authorize the grant of up to 16,000,000 shares of common stock to employees, directors, and consultants. On May 23, 2019, the board of directors approved the amendment and restatement of the 2017 Omnibus Incentive Plan, which increases the number of shares available for issuance under the 2017 plan by up to 500,000 shares, subject to the approval of the Company’s stockholders at the Company’s 2020 annual meeting of stockholders. Additionally, on June 14, 2017, the Company adopted its 2017 Employee Stock Purchase Plan (the “ESPP”), which authorizes the issuance of up to 1,000,000 shares of common stock for future issuances to eligible employees. Stock Options The total fair value of stock options vested and recorded as compensation expense during the three months ended September 30, 2019 and 2018, and nine months ended September 30, 2019 and 2018 was $2.0 million, $2.3 million, $5.8 million, and $7.6 million, respectively. As of September 30, 2019, $17.0 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.8 years. T he total intrinsic value of options exercised was approximately $1.8 million and $6.5 million for the nine months ended September 30, 2019 and 2018, respectively The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (aggregate intrinsic value in thousands): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 10,687,650 $ 8.51 6.87 $ 44,688 Granted 867,000 13.13 — — Exercised (217,234 ) 6.26 — — Forfeited and expired (159,473 ) 13.82 — — Outstanding at September 30, 2019 11,177,943 $ 8.83 5.91 $ 37,195 Vested and exercisable at September 30, 2019 8,497,160 $ 7.16 5.12 $ 42,506 The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding several highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine Months Ended Nine Months Ended September 30, 2019 September 30, 2018 Weighted average grant date fair value $ 8.04 $ 9.87 Expected dividend yield — % — % Expected stock price volatility 64 % 59 % Risk-free interest rate 2.61 % 2.60 % Expected life of options (in years) 6.3 6.1 Employee Stock Purchase Plan The ESPP is available to eligible employees (as defined in the plan document). Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from July 1, 2019 to November 30, 2019. The Company expects to offer six-month offering periods after the current period. The 2017 Plans reserved 1,000,000 shares of common stock for issuance under the ESPP. Stock-based compensation related to the ESPP amounted to $0.1 million for each of the three months ended September 30, 2019 and 2018, and $0.2 million and $0.1 million for the nine months ended September 30, 2019 and 2018, respectively. Restricted Stock Awards During the nine months ended September 30, 2019, the Company granted 92,723 restricted stock awards to employees in lieu of a cash bonus. Stock-based compensation related to this stock award amounted to $1.1 million for the nine months ended September 30, 2019. The Company granted 130,000 restricted stock awards to employees during the nine months ended September 30, 2019. Stock-based compensation related to the restricted stock awards amounted to $0.1 million for the three and nine months ended September 30, 2019. As of September 30, 2019, $1.9 million of unrecognized cost related to non-vested restricted stock awards were expected to be recognized over a weighted-average period of approximately 1.2 years. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Stock options $ 2,008 $ 2,316 $ 5,808 $ 7,558 Restricted stock expense 140 6 140 1,007 Stock grants to officers and employees — — 1,105 — Employee stock purchase plan 82 94 250 94 Total stock-based compensation expense $ 2,230 $ 2,416 $ 7,303 $ 8,659 Cost of sales $ 62 $ 64 $ 189 $ 164 Research and development expenses 746 688 2,251 1,915 Selling, general, and administrative expenses 1,422 1,664 4,863 6,580 Total stock-based compensation expense $ 2,230 $ 2,416 $ 7,303 $ 8,659

Net Loss per Share Attributable

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	13. Net Loss per Share Attributable to Athenex, Inc. Common Stockholders Basic net loss per share is calculated by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants to purchase common stock and stock options are considered common stock equivalents but are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Stock options and other common stock equivalents 11,634,810 11,119,444 11,004,831 10,397,140 Unvested restricted shares 49,457 4,891 16,667 152,808 Total potential dilutive shares 11,684,267 11,124,335 11,021,498 10,549,948

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	14. Business Segment, Geographic, and Concentration Risk Information The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows: Oncology Innovation Platform —This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. It focuses specifically on Orascovery and Src Kinase Inhibition research platforms, and TCR-T Immunotherapy and Arginine Deprivation Therapy. This segment operates in the United States, Taiwan, Hong Kong, mainland China, and the United Kingdom. Global Supply Chain Platform —This operating segment includes APS and Polymed. APS is a contract manufacturing company that provides small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and for use as internal supplies to the clinical studies and commercial development of the Company’s proprietary drugs. APS also performs microbiological and analytical testing for raw material and formulated products and has expanded to manufacture and sell pharmaceutical products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act (“FDCA”). Polymed markets and sells API in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds and processing techniques, and recently completed construction of a new API manufacturing facility in Chongqing, China. The 440,000-square-foot facility will produce validation batches in the fourth quarter of 2019 and is expected to commence commercial operations in the first half of 2020. The Company has an existing API manufacturing facility in Chongqing, China, where operations are currently suspended. Commercial Platform —This operating segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the United States. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, mainland China, and the United Kingdom. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue: Oncology Innovation Platform $ 115 $ 5,117 $ 421 $ 30,532 Global Supply Chain Platform 7,969 7,092 30,714 17,991 Commercial Platform 12,006 7,315 38,279 23,006 Total revenue for reportable segments 20,090 19,524 69,414 71,529 Intersegment revenue (726 ) (1,096 ) (2,546 ) (3,700 ) Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829 Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue by product group: API sales $ 3,647 $ 3,690 $ 12,308 $ 9,538 Medical device sales — 1,322 — 2,342 Contract manufacturing revenue 93 17 382 412 Commercial product sales 15,497 8,280 53,743 25,092 License fees — 5,000 — 30,000 Other revenue 127 119 435 445 Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829 Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (29,732 ) $ (37,638 ) $ (87,127 ) $ (65,985 ) Global Supply Chain Platform (3,376 ) (6,089 ) (3,829 ) (16,780 ) Commercial Platform (1,650 ) (2,443 ) (11,066 ) (7,562 ) Total consolidated net loss attributable to Athenex, Inc. $ (34,758 ) $ (46,170 ) $ (102,022 ) $ (90,327 ) Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total depreciation and amortization: Oncology Innovation Platform $ 227 $ 174 $ 626 $ 505 Global Supply Chain Platform 376 490 1,012 1,185 Commercial Platform 398 245 1,170 734 Total consolidated depreciation and amortization $ 1,001 $ 909 $ 2,808 $ 2,424 September 30, December 31, 2019 2018 Total assets: Oncology Innovation Platform $ 174,938 $ 135,878 Global Supply Chain Platform 65,833 58,816 Commercial Platform 46,824 36,401 Total consolidated assets $ 287,595 $ 231,095 Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue: United States $ 15,624 $ 9,559 $ 54,119 $ 27,405 India 1,684 259 3,066 1,701 China 563 306 1,837 1,917 South Korea 513 — 513 — Austria 476 2,227 4,423 5,102 Germany 398 — 602 — United Kingdom — — 1,023 — Spain — 5,000 — 30,000 Other foreign countries 106 1,077 1,285 1,704 Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829 September 30, December 31, 2019 2018 Total property and equipment, net: United States $ 10,791 $ 6,549 China 8,481 4,898 Total consolidated property and equipment, net $ 19,272 $ 11,447 Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Percentage of total revenue by customer: Customer A 17 % 12 % 20 % 13 % Customer B 22 % 11 % 17 % 8 % Customer C 17 % 13 % 16 % 9 % Customer D — 27 % — 44 % Customer E 2 % 10 % 6 % 6 % September 30, December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A 40 % 16 % Customer B 35 % 18 % Customer C 10 % 12 %

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue Recognition	15. Revenue Recognition The Company records revenue in accordance with ASC, Topic 606 “ Revenue from Contracts with Customers .” Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the entity performs the following five steps: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Below is a description of the principal activities – separated by reportable segments – from which the Company generates its revenue (See Note 14 – Business Segment, Geographic, and Concentration Risk Information ). 1. Oncology Innovation Platform License fees and consulting revenue The Company out-licenses certain of its IP and provides related consulting services to pharmaceutical companies in specific territories that allow the customer to use, develop, commercialize, or otherwise exploit the licensed IP. In accordance with Topic 606, the Company analyzes each of its out-licensing contracts with customers to identify each of the Company’s performance obligations within the contract. Each out-license contains multiple performance obligations. The Company has determined that each of its out-license agreements with customers are classified as functional licenses and are capable of being distinct, because the IP that is licensed carries standalone value and is not expected to be altered through the life of the agreement. Therefore, for each of its out-licensing agreements, the Company has determined that the execution of the license and delivery of the IP to the licensee is distinct from the other performance obligations identified in the arrangement within the context of the contract. The Company has considered the development services it is required to perform and determined that these services do not modify the license to the IP delivered. Also, the Company does not deem the license and the development services to be interdependent. As such, the Company records revenue at a point-in-time for its out-licensing if any of the transaction price is allocated to the obligation, including up-front licensing fee payments. The Company’s classification of each out-license as such requires significant judgment to be used by management. The Company considers the economic and regulatory characteristics of the licensed IP to determine if it has standalone value on the date of the licensing, which would make the licensing distinct and dictate that the Company recognizes any transaction price allocated to the license performance obligation at a point-in-time. Revenue recognized at a point-in-time for the execution of a distinct licensing of IP amounted to $0 Other performance obligations in the Company’s out-licensing agreements include reaching milestone development and regulatory events by performing research and development activities over the licensed IP. The Company reached a milestone event under an agreement with Almirall during the nine months ended September 30, 2019. The Company considers milestones to be variable consideration, as the entitlement to the consideration is contingent on the occurrence or nonoccurrence of future events. In addition to the multiple performance obligations, the Company’s out-licensing agreements include variable pricing. After the performance obligations are identified, the Company determines each portion of the transaction price, which generally includes upfront fees, milestone payments, and royalty payments. The Company begins by allocating the payments set forth in the agreement to the performance obligation to which the consideration is related. Then, the Company considers whether or not that transaction price is fixed, variable, or subject to return. If any portion of the transaction price is constrained by more than one performance obligation, the Company allocated that portion of the transaction price to the performance obligation that will be satisfied later and will not recognize revenue until it is fully satisfied and the constraint on the transaction price no longer exists. There are no other significant methods employed to allocate the transaction price to performance obligations in a contract. The Company exercises significant judgment when allocating the variable transaction prices to the proper performance obligations, considering if any of those payments are refundable or are contingent on any future events. Grant revenue The Company receives grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. Revenue is recognized when the underlying performance obligation is satisfied, which is generally when all grant eligibility criteria are met at a point-in-time. Grant revenue is not significant to the condensed consolidated financial statements. 2. Global Supply Chain Platform The Company’s Global Supply Chain Platform manufactures API for use internally in its research and development activities as well as its clinical studies, and for sale to pharmaceutical customers globally. The Company generates additional revenue on this platform, by providing small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and selling pharmaceutical products under 503B regulations set forth by the FDA. Revenue earned by the Global Supply Platform is recognized when the Company has satisfied its performance obligation, which is the shipment or the delivery of drug products. The underlying contracts for these sales are generally purchase orders and the Company recognizes revenue at a point-in-time. Any remaining performance obligations related to product sales are the result of customer deposits and are reflected in the deferred revenue contract liability balance. 3. Commercial Platform The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The wholesalers then sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end-user, the Company records a contra asset in accounts receivable and a reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user and such chargeback is offset against the initial estimated contra asset. The significant estimates inherent in the initial chargeback provision relate to wholesale units pending chargeback and to the ultimate end-user contract selling price. The Company bases the estimate for these factors on product-specific sales and internal chargeback processing experience, as well as estimated wholesaler inventory stocking levels. The Company also offers cash discounts, which approximate The Company also offers contractual allowances, generally rebates or administrative fees, to certain wholesale customers, group purchasing organizations (“GPOs”), and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to five months from date of sale. The Company provides a provision for contractual allowances at the time of sale based on the historical relationship between sales and such allowances. Contractual allowances are reflected in the condensed consolidated financial statements as a reduction of revenue and accounts receivable or as accrued expenses. The Company exercises significant judgment in its estimates of the variable transaction price at the time of the sale and recognizes revenue when the performance obligation is satisfied. Factors that determine the final net transaction price include chargebacks, fees for service, cash discounts, rebates, returns, warranties, and other factors. The Company estimates all of these variables based on historical data obtained from previous sales finalized with the end-user customer on a product-by-product basis. At the time of sale, revenue is recorded net of each of these deductions. Through the normal course of business, the wholesaler will sell the product to the end-user, determining the actual chargeback, return products, and take advantage of cash discounts, charge fees for services, and claim warranties on products. The final transaction price per product is compared to the initial estimated net sale price and reviewed for accuracy. The final prices and other factors are immediately included in the Company’s historical data from which it will estimate the transaction price for future sales. The underlying contracts for these sales are generally purchase orders including a single performance obligation, generally the shipment or delivery of products and the Company recognizes this revenue at a point-in-time. Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 3,618 $ 12,006 $ 15,624 India — 1,684 — 1,684 China 115 448 — 563 South Korea — 513 — 513 Austria — 476 — 476 Germany — 398 — 398 Other foreign countries — 106 — 106 Total revenue $ 115 $ 7,243 $ 12,006 $ 19,364 For the Three Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,244 $ 7,315 $ 9,559 Spain 5,000 — — 5,000 Austria — 2,227 — 2,227 China 117 189 — 306 India — 259 — 259 Other foreign countries — 1,077 — 1,077 Total revenue $ 5,117 $ 5,996 $ 7,315 $ 18,428 For the Nine Months Ended September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 15,840 $ 38,279 $ 54,119 Austria — 4,423 — 4,423 India — 3,066 — 3,066 China 421 1,416 — 1,837 United Kingdom — 1,023 — 1,023 Germany — 602 — 602 South Korea — 513 — 513 Other foreign countries — 1,285 — 1,285 Total revenue $ 421 $ 28,168 $ 38,279 $ 66,868 For the Nine Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Spain $ 30,000 $ — $ — $ 30,000 United States — 4,399 23,006 27,405 Austria — 5,102 — 5,102 China 532 1,385 — 1,917 India — 1,701 — 1,701 Other foreign countries — 1,704 — 1,704 Total revenue $ 30,532 $ 14,291 $ 23,006 $ 67,829 The Company also disaggregates its revenue by product group which can be found in Note 14 – Business Segment, Geographic, and Concentration Risk Information Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. September 30, 2019 December 31, 2018 (In Thousands) Accounts receivable, gross $ 37,210 $ 26,061 Chargebacks and other deductions (19,909 ) (13,101 ) Allowance for doubtful accounts (133 ) (9 ) Accounts receivable, net $ 17,168 $ 12,951 Deferred revenue 20,071 190 Total contract liabilities $ 20,071 $ 190 The following tables illustrate accounts receivable balances by reportable segments. September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 4,888 $ 32,322 $ 37,210 Allowance for doubtful accounts, chargebacks, and other deductions — (120 ) (19,922 ) (20,042 ) Accounts receivable, net $ — $ 4,768 $ 12,400 $ 17,168 December 31, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 7,814 $ 18,247 $ 26,061 Allowance for doubtful accounts, chargebacks, and other deductions — (9 ) (13,101 ) (13,110 ) Accounts receivable, net $ — $ 7,805 $ 5,146 $ 12,951 As of September 30, 2019, $20.0 million of the deferred revenue balance relates to a license milestone payment received pursuant to an agreement held by the Oncology Innovation Platform and $0.1 As of December 31, 2018, the $0.2 million contract liability related to customer deposits made by customers of the Global Supply Chain Platform. The Company satisfied its performance obligations allocated to these contract liabilities during the nine months ended September 30, 2019. Practical expedients used During the adoption of ASC 606, the Company applied the practical expedient in paragraph 606-10-10-4, the Portfolio Approach The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations related to the license of IP. This practical expedient is applied because the out-licensing agreements include sales-based royalties in exchange for the license of IP accounted for in accordance with Topic 606 and there is significant uncertainty surrounding the future variable consideration that could be received.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Future minimum payments under the non-cancelable operating lease consists of the following as of December 31, 2018 (in thousands): Year ending December 31: Minimum payments 2019 $ 2,943 2020 2,466 2021 2,040 2022 1,902 2023 1,675 Thereafter 3,099 $ 14,125 Legal Proceedings From time to time, the Company may be subject to claims and litigation arising in the ordinary course of business. These claims could include assertions that the Company’s products infringe existing patents or claims that the use of its products has caused personal injuries. The Company intends to vigorously defend any such litigation that may arise under all defenses that would be available. Regardless of the outcome, litigation can have an adverse impact on the Company because of prosecution, defense and settlement costs, unfavorable awards, diversion of management resources and other factors. Vasopressin (Generic version of Vasostrict®) On August 13, 2018, APS and APD, our wholly-owned subsidiaries, filed a complaint for declaratory judgment against Par Pharmaceuticals, Inc., Par Sterile Products, LLC and Endo Par Innovation Company, LLC (together, “Par”) in the United States District Court for the Western District of New York (the “Court”), seeking a declaratory judgment from the Court that our compounded vasopressin drug products in ready-to-use form did not infringe on patents that Par has with respect to its Vasostrict® product and that Par’s patents are invalid. On July 9, 2019, the Court ordered dismissal of our complaint for lack of subject matter jurisdiction. We did not appeal this dismissal. While Par has not alleged that our compounded vasopressin infringed any of its patents, Par could do so by commencing an infringement lawsuit against us. If such an infringement lawsuit were brought and a court ruled for Par, Athenex could be enjoined from further production of compounded vasopressin within in the United States and sale of compounded vasopressin in or from the United States and for payment of damages to Par for U.S. manufacture or sale of compounded vasopressin that has already taken place. In addition, on August 13, 2018, APS and APD filed a motion to intervene and seek the dismissal of Par Sterile Products, LLC’s and Endo Par Innovation Company, LLC’s complaint against the FDA and certain governmental officials in the United States District Court for the District of Columbia (the “DC Court”). Our motion to intervene was granted. These two Par entities have sought declaratory and injunctive relief, including a preliminary injunction, against FDA and certain governmental officials that: (i) vasopressin be delisted from Category 1 of FDA’s list of bulk drug substances under evaluation pursuant to Section 503B of the FDCA, (ii) the expansion of FDA’s enforcement discretion to Category 1 substances, be enjoined; and (iii) that FDA be enjoined from authorizing the compounding of vasopressin under Section 503B of the FDCA. We and FDA filed motions for judgment on the pleadings. On February 7, 2019, before resolving the above pending motions, the DC Court stayed the case until the earlier of: (i) March 15, 2019; (ii) FDA publishes in the Federal Register a final determination about whether to include vasopressin on the clinical need list; or (iii) Par notify the Parties and the Court of a substantial change in circumstances necessitating a decision on Plaintiffs' Motion for Preliminary Injunction. On March 4, 2019, FDA published in the Federal Register its final decision not to include vasopressin on the list of bulk drug substances for which there is a clinical need. On the same day, we (Athenex, Inc., APS, and APD) filed a complaint in the DC Court against FDA seeking to vacate its final decision. Par Sterile Products, LLC and Endo Par Innovation Company, LLC joined this case as intervenors. On March 11, 2019, the DC Court extended the stay of Par’s lawsuit against FDA until resolution of the motions for summary judgment in this newer related case. In our case against the FDA, the FDA represented to the DC Court that “until the Court issues a decision on the merits of this action, the FDA will not initiate enforcement action against Athenex based solely on Athenex’s use of the bulk drug substance vasopressin to compound drugs and distribute those drugs” and the DC Court incorporated the FDA’s representation into its published order. As such, Athenex produced and distributed compounded vasopressin during the period that the case was pending before the DC District Court and prior to its decision. On April 30, 2019, the DC Court held a hearing on the parties’ cross motions for summary judgment. On August 1, 2019, the DC Court issued a ruling upholding the FDA’s vasopressin decision and dismissing Athenex’s complaint. On August 2, 2019, Athenex then filed a motion for voluntary dismissal of the appeal. On October 1, 2019, the DC Court granted our motion to voluntarily dismiss the appeal and dismissed the case. Par filed a motion to voluntarily dismiss its complaint against the FDA and certain governmental officials in the DC Court. Athenex did not oppose this motion and, on September 27, 2019, the DC Court granted Par’s motion to dismiss the action and dismissed the case. since the DC Court’s August 1, 2019 decision

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On October 31, 2019, the Company consummated the asset acquisition of CIDAL (see Note 7 – Acquisitions

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, do not include all of the information the opinion of management, reflect all normal recurring adjustments necessary a fair of the results for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been eliminated Results of the Company’s operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results expected for the year ending December 31, 2019, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, allowance for doubtful accounts, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.
Leases	Leases On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the contractual terms of the operating leases. The Company uses its incremental borrowing rate based on the information available at the date of initial adoption in determining the present value of the future lease payments. The Company uses the stated rate per each lease agreement in determining the finance lease liabilities. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. The lease liabilities and ROU asset are amortized over the term of the lease with operating lease expenses being recognized on a straight-line basis over the lease terms. The Company elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term leases.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, " Leases (Topic 842), The Company adopted the new lease standard on January 1, 2019 and used the effective date as the date of initial application. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company also elected the single component practical expedient, which requires the Company, by class of underlying asset, not to allocate the total consideration to the lease and nonlease components based on their relative stand-alone selling prices. This single component practical expedient requires the Company to account for the lease component and nonlease component(s) associated with that lease as a single component if (i) the timing and pattern of transfer of the lease component and the nonlease component(s) associated with it are the same and (ii) the lease component would be classified as an operating lease if it were accounted for separately. In preparation for adoption of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard had a material impact on the consolidated balance sheet, with no material impact on its consolidated statement of operations and comprehensive loss. On the adoption date, the Company recognized $9.8 million of operating lease ROU assets, $11.9 million of operating lease liabilities, and derecognized its existing deferred rent balance of $2.1 million. In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation – Stock Compensation Recently Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Measurement of Credit Losses on Financial Instruments”

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): September 30, 2019 December 31, 2018 Raw materials and purchased parts $ 3,597 $ 4,092 Work in progress 2,012 3,166 Finished goods 22,842 21,529 Total inventories $ 28,451 $ 28,787

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): September 30, 2019 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 8,935 $ 3,184 $ — $ 5,751 Polymed customer list 1,593 1,101 — 492 Polymed technology 3,712 1,194 — 2,518 Product rights 525 360 165 — Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 715 — — 715 Effect of currency translation adjustment (504 ) — — (504 ) Total intangible assets, net $ 14,976 $ 5,839 $ 165 $ 8,972 December 31, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 2,060 $ — $ 6,875 Polymed customer list 1,593 938 — 655 Polymed technology 3,712 999 — 2,713 Product rights 530 263 — 267 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — 298 728 Effect of currency translation adjustment (390 ) — — (390 ) Total intangibles, net $ 15,406 $ 4,260 $ 298 $ 10,848

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at September 30, 2019 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 32 $ 32 $ — $ — Short-term investments - commercial paper 21,164 — 21,164 — Financial assets included within short-term investments Short-term investments - certificates of deposit 10,000 — 10,000 — Short-term investments - commercial paper 32,022 — 32,022 — Available-for-sale investment 251 251 — — Total assets $ 63,469 $ 283 $ 63,186 $ — Fair Value Measurements at December 31, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 25 $ 25 $ — $ — Short-term investments - commercial paper 5,396 — 5,396 — Financial assets included within short-term investments Short-term investments - commercial paper 36,544 — 36,544 — Short-term investments - corporate notes 16,699 — 16,699 — Short-term investments - U.S. government bonds 3,998 — 3,998 — Available-for-sale investment 388 388 — — Total assets $ 63,050 $ 413 $ 62,637 $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2019
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): September 30, December 31, 2019 2018 Accrued wages and benefits $ 6,277 $ 5,061 Accrued clinical expenses 2,848 2,653 Accrued operating expenses 5,994 8,128 Deferred revenue 20,071 190 Accrued R&D licensing fees 382 4,827 Accrued tax withholdings 256 — Accrued selling fees and rebates 1,436 423 Accrued construction costs 32,730 16,436 Total accrued expenses $ 69,994 $ 37,718

Debt and Lease Obligations (Tab

Debt and Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2019
Debt And Lease Obligations [Abstract]
Schedule of Debt	The Company’s debt as of September 30, 2019 and December 31, 2018, consists of the following (in thousands): September 30, December 31, 2019 2018 Current portion of mortgage $ 70 $ 779 Current portion of bank loan 697 — Current portion of finance and capital lease obligations 191 182 Current portion of operating lease obligations 2,810 — Long-term portion of finance and capital lease obligations 277 422 Long-term portion of operating lease obligations 7,579 — Long-term portion of mortgage 670 — Chongqing Maliu Credit Agreement 5,583 — Senior secured loan, net of debt discount and financing fees of $3,849 and $4,619, respectively 46,151 45,381 Total $ 64,028 $ 46,764
Summary of Components of Lease Expense	The components of lease expense are as follows (in thousands): Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 793 $ 2,365 Finance lease cost: Amortization of assets 21 46 Interest on lease liabilities 7 24 Total net lease cost $ 821 $ 2,435
Schedule of Supplemental Balance Sheet Information Related to Leases of Debt	Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): September 30, 2019 Operating leases: Operating lease ROU assets, net $ 8,517 Current operating lease liabilities $ 2,810 Long-term operating lease liabilities 7,579 Total operating lease liabilities $ 10,389 Finance leases: Property and equipment, at cost $ 660 Accumulated amortization, net (46 ) Property and equipment, net $ 614 Current obligations of finance leases $ 191 Long-term portion of finance leases 277 Total finance lease obligations $ 468 Weighted average remaining lease term (in years): Operating leases 5.54 Finance leases 2.36 Weighted average discount rate: Operating leases 13.0 % Finance leases 5.9 %
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows (in thousands): Nine Months Ended September 30, 2019 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ 2,515 Operating cash flows from finance leases 24 Financing cash flows from finance leases 136 ROU assets recognized in exchange for new operating lease obligations $ 583
Schedule of Future Minimum Payments and Maturities of Leases	Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2019 (remaining three months) $ 823 $ 54 2020 2,941 214 2021 2,534 214 2022 2,354 21 2023 2,095 — Thereafter 3,952 — Total lease payments 14,699 503 Less: Imputed interest (4,310 ) (35 ) Total lease obligations 10,389 468 Less: Current obligations (2,810 ) (191 ) Long-term lease obligations $ 7,579 $ 277

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (aggregate intrinsic value in thousands): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 10,687,650 $ 8.51 6.87 $ 44,688 Granted 867,000 13.13 — — Exercised (217,234 ) 6.26 — — Forfeited and expired (159,473 ) 13.82 — — Outstanding at September 30, 2019 11,177,943 $ 8.83 5.91 $ 37,195 Vested and exercisable at September 30, 2019 8,497,160 $ 7.16 5.12 $ 42,506
Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model	The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding several highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine Months Ended Nine Months Ended September 30, 2019 September 30, 2018 Weighted average grant date fair value $ 8.04 $ 9.87 Expected dividend yield — % — % Expected stock price volatility 64 % 59 % Risk-free interest rate 2.61 % 2.60 % Expected life of options (in years) 6.3 6.1
Schedule of Stock-Based Compensation Cost	The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Stock options $ 2,008 $ 2,316 $ 5,808 $ 7,558 Restricted stock expense 140 6 140 1,007 Stock grants to officers and employees — — 1,105 — Employee stock purchase plan 82 94 250 94 Total stock-based compensation expense $ 2,230 $ 2,416 $ 7,303 $ 8,659 Cost of sales $ 62 $ 64 $ 189 $ 164 Research and development expenses 746 688 2,251 1,915 Selling, general, and administrative expenses 1,422 1,664 4,863 6,580 Total stock-based compensation expense $ 2,230 $ 2,416 $ 7,303 $ 8,659

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Stock options and other common stock equivalents 11,634,810 11,119,444 11,004,831 10,397,140 Unvested restricted shares 49,457 4,891 16,667 152,808 Total potential dilutive shares 11,684,267 11,124,335 11,021,498 10,549,948

Business Segment, Geographic,_2

Business Segment, Geographic, and Concentration Risk Information (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Summary of Revenue by Segments	Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue: Oncology Innovation Platform $ 115 $ 5,117 $ 421 $ 30,532 Global Supply Chain Platform 7,969 7,092 30,714 17,991 Commercial Platform 12,006 7,315 38,279 23,006 Total revenue for reportable segments 20,090 19,524 69,414 71,529 Intersegment revenue (726 ) (1,096 ) (2,546 ) (3,700 ) Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829
Summary of Revenue by Product Group	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue by product group: API sales $ 3,647 $ 3,690 $ 12,308 $ 9,538 Medical device sales — 1,322 — 2,342 Contract manufacturing revenue 93 17 382 412 Commercial product sales 15,497 8,280 53,743 25,092 License fees — 5,000 — 30,000 Other revenue 127 119 435 445 Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829
Summary of Segment Information	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (29,732 ) $ (37,638 ) $ (87,127 ) $ (65,985 ) Global Supply Chain Platform (3,376 ) (6,089 ) (3,829 ) (16,780 ) Commercial Platform (1,650 ) (2,443 ) (11,066 ) (7,562 ) Total consolidated net loss attributable to Athenex, Inc. $ (34,758 ) $ (46,170 ) $ (102,022 ) $ (90,327 )
Summary of Depreciation, Amortization and Assets by Segment	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total depreciation and amortization: Oncology Innovation Platform $ 227 $ 174 $ 626 $ 505 Global Supply Chain Platform 376 490 1,012 1,185 Commercial Platform 398 245 1,170 734 Total consolidated depreciation and amortization $ 1,001 $ 909 $ 2,808 $ 2,424 September 30, December 31, 2019 2018 Total assets: Oncology Innovation Platform $ 174,938 $ 135,878 Global Supply Chain Platform 65,833 58,816 Commercial Platform 46,824 36,401 Total consolidated assets $ 287,595 $ 231,095
Summary of Revenue by Geographical Segment	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total revenue: United States $ 15,624 $ 9,559 $ 54,119 $ 27,405 India 1,684 259 3,066 1,701 China 563 306 1,837 1,917 South Korea 513 — 513 — Austria 476 2,227 4,423 5,102 Germany 398 — 602 — United Kingdom — — 1,023 — Spain — 5,000 — 30,000 Other foreign countries 106 1,077 1,285 1,704 Total consolidated revenue $ 19,364 $ 18,428 $ 66,868 $ 67,829
Summary of Property and Equipment by Geographical Segment	September 30, December 31, 2019 2018 Total property and equipment, net: United States $ 10,791 $ 6,549 China 8,481 4,898 Total consolidated property and equipment, net $ 19,272 $ 11,447
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Percentage of total revenue by customer: Customer A 17 % 12 % 20 % 13 % Customer B 22 % 11 % 17 % 8 % Customer C 17 % 13 % 16 % 9 % Customer D — 27 % — 44 % Customer E 2 % 10 % 6 % 6 % September 30, December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A 40 % 16 % Customer B 35 % 18 % Customer C 10 % 12 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer	Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 3,618 $ 12,006 $ 15,624 India — 1,684 — 1,684 China 115 448 — 563 South Korea — 513 — 513 Austria — 476 — 476 Germany — 398 — 398 Other foreign countries — 106 — 106 Total revenue $ 115 $ 7,243 $ 12,006 $ 19,364 For the Three Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,244 $ 7,315 $ 9,559 Spain 5,000 — — 5,000 Austria — 2,227 — 2,227 China 117 189 — 306 India — 259 — 259 Other foreign countries — 1,077 — 1,077 Total revenue $ 5,117 $ 5,996 $ 7,315 $ 18,428 For the Nine Months Ended September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 15,840 $ 38,279 $ 54,119 Austria — 4,423 — 4,423 India — 3,066 — 3,066 China 421 1,416 — 1,837 United Kingdom — 1,023 — 1,023 Germany — 602 — 602 South Korea — 513 — 513 Other foreign countries — 1,285 — 1,285 Total revenue $ 421 $ 28,168 $ 38,279 $ 66,868 For the Nine Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Spain $ 30,000 $ — $ — $ 30,000 United States — 4,399 23,006 27,405 Austria — 5,102 — 5,102 China 532 1,385 — 1,917 India — 1,701 — 1,701 Other foreign countries — 1,704 — 1,704 Total revenue $ 30,532 $ 14,291 $ 23,006 $ 67,829
Summary of Receivables and Contract Liabilities From Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. September 30, 2019 December 31, 2018 (In Thousands) Accounts receivable, gross $ 37,210 $ 26,061 Chargebacks and other deductions (19,909 ) (13,101 ) Allowance for doubtful accounts (133 ) (9 ) Accounts receivable, net $ 17,168 $ 12,951 Deferred revenue 20,071 190 Total contract liabilities $ 20,071 $ 190
Summary of Accounts Receivable Balances by Reportable Segments	The following tables illustrate accounts receivable balances by reportable segments. September 30, 2019 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 4,888 $ 32,322 $ 37,210 Allowance for doubtful accounts, chargebacks, and other deductions — (120 ) (19,922 ) (20,042 ) Accounts receivable, net $ — $ 4,768 $ 12,400 $ 17,168 December 31, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 7,814 $ 18,247 $ 26,061 Allowance for doubtful accounts, chargebacks, and other deductions — (9 ) (13,101 ) (13,110 ) Accounts receivable, net $ — $ 7,805 $ 5,146 $ 12,951

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable operating lease consists of the following as of December 31, 2018 (in thousands): Year ending December 31: Minimum payments 2019 $ 2,943 2020 2,466 2021 2,040 2022 1,902 2023 1,675 Thereafter 3,099 $ 14,125

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May 07, 2019	Jul. 03, 2018	Feb. 28, 2018	Jan. 31, 2018	Jun. 30, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Subsidiary Or Equity Method Investee [Line Items]
Aggregate net proceeds from stock issuance								$ 100,373	$ 122,666
Sale of common stock					$ 100,319	$ 49,093	$ 68,055
Payments for offering expenses								54	$ 5,118
Accumulated deficit								545,738		$ 443,716
Cash cash equivalents restricted cash and short-term investments								$ 129,200
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold					10,033,362	2,679,528	4,765,000
Sale of common stock					$ 10	$ 3	$ 4
Share Purchase Agreement
Subsidiary Or Equity Method Investee [Line Items]
Private placement closing date	May 7, 2019
Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Warrants to purchase common stock outstanding		425,000
Warrants to purchase common stock, share price		$ 18.66
Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold		2,679,528
Common stock share price		$ 18.66
Gross proceeds from debt and equity financing		$ 100,000
Aggregate net proceeds of debt and equity financing, net of fees and offering expenses		97,100
Sale of common stock		$ 50,000
Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Debt instrument maturity term		5 years
Convertible bonds, aggregate principal value		$ 50,000
LIBOR | Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Debt variable rate basis floor		2.00%
Basis spread on variable rate		9.00%
Underwriters
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold				4,300,000
Common stock share price			$ 15.25	$ 15.25
Number of days granted to underwriters option to purchase additional shares				30 days
Number of additional common stock shares purchase			465,000	645,000
Aggregate net proceeds from stock issuance			$ 68,100
Underwriting discounts and commissions and offering expenses			$ 4,600
Private Placement | Share Purchase Agreement
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price	$ 10
Net proceeds from issuance of private placement	$ 99,900
Payments for offering expenses	$ 100
Private Placement | Share Purchase Agreement | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold	10,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Accounting Policies [Abstract]
Operating lease ROU assets	$ 8,517	$ 9,800
Operating lease liabilities	$ 10,389	11,900
Deferred rent balance derecognized		$ 2,100

Restricted Cash - Additional In

Restricted Cash - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Restricted Cash [Line Items]
Restricted cash balance	$ 25,424
Letter of credit expiration date	Dec. 15, 2019
Secured Deposits
Restricted Cash [Line Items]
Restricted cash balance	$ 25,000
Restricted Cash Deposits as Security
Restricted Cash [Line Items]
Restricted cash balance	$ 400

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 3,597	$ 4,092
Work in progress	2,012	3,166
Finished goods	22,842	21,529
Total inventories	$ 28,451	$ 28,787

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization	$ 5,839	$ 4,260
Intangible asset, Effect of currency translation adjustment	(504)	(390)
Intangible assets Cost/Fair Value	14,976	15,406
Intangible assets Impairments	165	298
Intangible assets, net	8,972	10,848
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	715	1,026
Indefinite-lived intangible asset, Impairments		298
Indefinite-lived intangible asset, Net	715	728
Licensing Agreements
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	8,935	8,935
Finite-lived intangible asset, Accumulated Amortization	3,184	2,060
Finite-lived intangible asset, Net	5,751	6,875
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593	1,593
Finite-lived intangible asset, Accumulated Amortization	1,101	938
Finite-lived intangible asset, Net	492	655
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712	3,712
Finite-lived intangible asset, Accumulated Amortization	1,194	999
Finite-lived intangible asset, Net	2,518	2,713
Product Rights
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	525	530
Finite-lived intangible asset, Accumulated Amortization	360	263
Finite-lived intangible asset, Impairments	$ 165
Finite-lived intangible asset, Net		$ 267

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			$ 165		$ 298
Weighted-average useful life of intangible assets			7 years 8 months 12 days
Amortization expense of intangible assets	$ 500	$ 400	$ 1,400	$ 1,200
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments	$ 200		200
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 400
Acquired finite-lived intangible assets, amortization period			12 years 9 months
Licensing Agreements | Gland Pharma Limited
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 4,300
Acquired finite-lived intangible assets, amortization period			5 years
Licensing Agreements | MAIA Pharmaceuticals, Inc
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 4,000
Acquired finite-lived intangible assets, amortization period			7 years
Customer List | APS
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			12 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0
Fair value assets, transfers into Level 3	0	0
Fair value assets, transfers out of Level 3	0	0
Fair value liabilities, transfers into Level 3	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0
Pharma Essentia | OTC | Taiwan | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets:
Total assets	$ 63,469	$ 63,050
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	283	413
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	63,186	62,637
Money Market Funds | Cash and Cash Equivalents
Assets:
Total assets	32	25
Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Assets:
Total assets	32	25
Short-term Investments - Certificates of Deposit | Short-term Investments
Assets:
Total assets	10,000
Short-term Investments - Certificates of Deposit | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	10,000
Short-term Investments - Commercial Paper | Short-term Investments
Assets:
Total assets	32,022	36,544
Short-term Investments - Commercial Paper | Cash and Cash Equivalents
Assets:
Total assets	21,164	5,396
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	32,022	36,544
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets	21,164	5,396
Available-for-Sale Investment | Short-term Investments
Assets:
Total assets	251	388
Available-for-Sale Investment | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments
Assets:
Total assets	$ 251	388
Short-term Investments - Corporate Notes | Short-term Investments
Assets:
Total assets		16,699
Short-term Investments - Corporate Notes | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets		16,699
Short-term investments - U.S. Government Bonds | Short-term Investments
Assets:
Total assets		3,998
Short-term investments - U.S. Government Bonds | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets		$ 3,998

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 27, 2019	Jun. 29, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Asset Acquisition [Line Items]
Goodwill			$ 37,293			$ 37,293		$ 37,495
Research and development licensing fee satisfied with stock				$ 29,545	$ 2,000
Research and development expenses			19,588	$ 51,202		62,570	$ 99,077
Axis Therapeutics Limited
Asset Acquisition [Line Items]
Capital contributions to joint venture		$ 30,000	30,000			$ 30,000
Percentage of ownership in joint venture		55.00%				55.00%
Axis Therapeutics Limited | Research and Development Expenses
Asset Acquisition [Line Items]
Research and development expenses								$ 24,500
Axis Therapeutics Limited | Licensing Agreements
Asset Acquisition [Line Items]
Research and development licensing fee satisfied with stock, shares		267,952
Research and development licensing fee satisfied with stock		$ 5,000
Axis Therapeutics Limited | XLifeSc | IPR & D
Asset Acquisition [Line Items]
Percentage of ownership in joint venture		45.00%
Percentage of nonmonetary exchange of shares						45.00%
Fair value of equity shares issued			$ 24,500			$ 24,500
Common Stock
Asset Acquisition [Line Items]
Research and development licensing fee satisfied with stock, shares				267,952	107,181
CIDAL Limited
Asset Acquisition [Line Items]
Asset purchase agreement closing date	Oct. 31, 2019
Purchase price	$ 2,200
Liabilities assumed	1,100
Contingent consideration paid	1,100
Cash received	800
Goodwill	1,400
CIDAL Limited | Maximum [Member]
Asset Acquisition [Line Items]
Fixed assets	$ 100
CIDAL Limited | Common Stock
Asset Acquisition [Line Items]
Business acquisition, assumed liabilities and milestone payments aggregate share consideration	67,796

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expensest (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued wages and benefits	$ 6,277	$ 5,061
Accrued clinical expenses	2,848	2,653
Accrued operating expenses	5,994	8,128
Deferred revenue	20,071	190
Accrued R&D licensing fees	382	4,827
Accrued tax withholdings	256
Accrued selling fees and rebates	1,436	423
Accrued construction costs	32,730	16,436
Total accrued expenses	$ 69,994	$ 37,718

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities [Line Items]
Deferred revenue	$ 20,071	$ 190
Out-license Revenue
Accrued Liabilities [Line Items]
Deferred revenue	20,000
Dunkirk, NY | Manufacturing Facility | Prepaid Expenses and Other Current Assets
Accrued Liabilities [Line Items]
Accrued construction costs to be reimbursed	$ 32,100

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax [Line Items]
Income tax expense (benefit)	$ 114,000	$ (30,000)	$ 1,019,000	$ (286,000)
Federal
Income Tax [Line Items]
Income tax expense (benefit)			$ 0

Debt and Lease Obligations - Su

Debt and Lease Obligations - Summary of Balances of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Current portion of mortgage	$ 70	$ 779
Current portion of bank loan	697
Current portion of finance and capital lease obligations	191	182
Current portion of operating lease obligations	2,810
Long-term portion of finance and capital lease obligations	277	422
Long-term portion of operating lease obligations	7,579
Long-term portion of mortgage	670
Total	64,028	46,764
Chongqing Maliu Credit Agreement
Debt Instrument [Line Items]
Chongqing Maliu Credit Agreement	5,583
Senior Secured Loan
Debt Instrument [Line Items]
Senior secured loan, net of debt discount and financing fees of $3,849 and $4,619, respectively	$ 46,151	$ 45,381

Debt and Lease Obligations - _2

Debt and Lease Obligations - Summary of Balances of Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Senior Secured Loan
Debt Instrument [Line Items]
Debt discount and financing fees	$ 3,849	$ 4,619

Debt and Lease Obligations - Ad

Debt and Lease Obligations - Additional Information (Detail) ¥ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2019CNY (¥)	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)
Debt Instrument [Line Items]
Mortgage payment extended date			Dec. 31, 2020
Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”)
Debt Instrument [Line Items]
Line of credit facility percentage of periodic payment year one	20
Line of credit facility percentage of periodic payment year two	30
Line of credit frequency of payments			The Company is required to repay the principal amount with accrued interest within three years after the plant receives the U.S. Current Good Manufacturing Practices (“cGMP”) certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months.
Line of credit due			$ 5,583,000
China | Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”)
Debt Instrument [Line Items]
Long-term line of credit | ¥	¥ 50
Unsecured, Subordinated Bank Loan from China Merchants Bank | China
Debt Instrument [Line Items]
Convertible bonds, aggregate principal value		$ 700,000
Debt maturity date		Dec. 11, 2019
Interest rate		5.70%
Senior Secured Loan
Debt Instrument [Line Items]
Convertible bonds, aggregate principal value			$ 50,000
Debt maturity date			Jun. 30, 2023
Senior Secured Loan | LIBOR
Debt Instrument [Line Items]
Debt variable rate basis floor			2.00%
Basis spread on variable rate			9.00%

Debt and Lease Obligations - _3

Debt and Lease Obligations - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Debt And Lease Obligations [Abstract]
Operating lease cost	$ 793	$ 2,365
Finance lease cost:
Amortization of assets	21	46
Interest on lease liabilities	7	24
Total net lease cost	$ 821	$ 2,435

Debt and Lease Obligations - Sc

Debt and Lease Obligations - Schedule of Supplemental Balance Sheet Information Related to Leases of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Operating leases:
Operating lease ROU assets, net	$ 8,517	$ 9,800
Current operating lease liabilities	2,810
Long-term operating lease liabilities	7,579
Total operating lease liabilities	10,389	$ 11,900
Finance leases:
Property and equipment, at cost	660
Accumulated amortization, net	(46)
Property and equipment, net	$ 614
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet
Current obligations of finance leases	$ 191
Long-term portion of finance leases	277
Total finance lease obligations	$ 468
Weighted average remaining lease term (in years):
Operating leases	5 years 6 months 14 days
Finance leases	2 years 4 months 9 days
Weighted average discount rate:
Operating leases	13.00%
Finance leases	5.90%

Debt and Lease Obligations - _4

Debt and Lease Obligations - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Cash paid for amount included in the measurements of lease liabilities:
Operating cash flows from operating leases	$ 2,515
Operating cash flows from finance leases	24
Financing cash flows from finance leases	136
ROU assets recognized in exchange for new operating lease obligations	$ 583

Debt and Lease Obligations - _5

Debt and Lease Obligations - Schedule of Future Minimum Payments and Maturities of Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Operating Leases
2019 (remaining three months)	$ 823
2020	2,941
2021	2,534
2022	2,354
2023	2,095
Thereafter	3,952
Total lease payments	14,699
Less: Imputed interest	(4,310)
Total operating lease liabilities	10,389	$ 11,900
Less: Current obligations	(2,810)
Long-term lease obligations	7,579
Finance Leases
2019 (remaining three months)	54
2020	214
2021	214
2022	21
Total lease payments	503
Less: Imputed interest	(35)
Total finance lease obligations	468
Less: Current obligations	(191)
Long-term portion of finance leases	$ 277

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2018Agreement	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Jun. 30, 2019	Sep. 30, 2019USD ($)Executiveshares	Sep. 30, 2018USD ($)	Dec. 31, 2018shares
Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership in joint venture				10.00%
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares		786,061			786,061		786,061
Percentage of common stock issued shares					1.00%		1.00%
Avalon BioMedical | Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership interest				90.00%
Avalon BioMedical | In-licensing Agreement
Related Party Transaction [Line Items]
Number of in-licensing agreements | Agreement	2
Payment of upfront fees		$ 1,000,000	$ 0		$ 1,000,000	$ 5,500,000
Payment of upfront fees in cash						3,500,000
Payment of upfront fees in equity						2,000,000
Pharma Essentia
Related Party Transaction [Line Items]
Licenses revenue		0	0		0	0
Funds paid to related party		200,000			$ 200,000
Funds received from related party			0			300,000
Executive Officer
Related Party Transaction [Line Items]
Number of executives | Executive					1
ZenRx
Related Party Transaction [Line Items]
Licenses revenue		0	0		$ 0	0
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received		$ 1,800,000	$ 100,000		$ 2,400,000	$ 300,000

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	May 23, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 2,230	$ 2,416	$ 7,303	$ 8,659
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		2,008	2,316	5,808	7,558
Unrecognized compensation cost related to non-vested stock options expected to be recognized		17,000		$ 17,000
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition				1 year 9 months 18 days
Total intrinsic value of stock options exercised				$ 1,800	6,500
Stock Grants to Officers and Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 1,105
Shares granted to employees				92,723
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		140	6	$ 140	1,007
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition				1 year 2 months 12 days
Shares granted to employees				130,000
Unrecognized cost related to non-vested restricted stock awards		$ 1,900		$ 1,900
Maximum [Member] | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		1,000,000		1,000,000
2017, 2013, 2007 and 2004 Plans | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options authorized grant		16,000,000		16,000,000
2017 Omnibus Incentive Plan | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in stock available for issuance under plan	500,000
2017 Plans | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		1,000,000		1,000,000
Stock-based compensation expense		$ 100	$ 100	$ 200	$ 100
Percentage of discount on purchase price of common stock				15.00%
Employee stock purchase plan, description				Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from July 1, 2019 to November 30, 2019. The Company expects to offer six-month offering periods after the current period.

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Stock Options
Stock Options, Outstanding Beginning Balance | shares	10,687,650
Stock Options, Granted | shares	867,000
Stock Options, Exercised | shares	(217,234)
Stock Options, Forfeited and expired | shares	(159,473)
Stock Options, Outstanding Ending Balance | shares	11,177,943	10,687,650
Stock Options, Vested and exercisable | shares	8,497,160
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 8.51
Weighted Average Exercise Price, Granted | $ / shares	13.13
Weighted Average Exercise Price, Exercised | $ / shares	6.26
Weighted Average Exercise Price, Forfeited and expired | $ / shares	13.82
Weighted Average Exercise Price, Outstanding Ending Balance | $ / shares	8.83	$ 8.51
Weighted Average Exercise Price, Vested and exercisable | $ / shares	$ 7.16
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	5 years 10 months 28 days	6 years 10 months 13 days
Weighted Average Remaining Contractual Term, Vested and exercisable	5 years 1 month 13 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding | $	$ 37,195	$ 44,688
Aggregate Intrinsic Value, Vested and exercisable | $	$ 42,506

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 8.04	$ 9.87
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	64.00%	59.00%
Risk-free interest rate	2.61%	2.60%
Expected life of options (in years)	6 years 3 months 18 days	6 years 1 month 6 days

Stock Based Compensation - Sc_3

Stock Based Compensation - Schedule of Stock-Based Compensation Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 2,230	$ 2,416	$ 7,303	$ 8,659
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	2,008	2,316	5,808	7,558
Restricted Stock Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	140	6	140	1,007
Stock Grants to Officers and Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized			1,105
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	82	94	250	94
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	62	64	189	164
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	746	688	2,251	1,915
Selling, General, and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 1,422	$ 1,664	$ 4,863	$ 6,580

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	11,684,267	11,124,335	11,021,498	10,549,948
Stock Options and Other Common Stock Equivalents
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	11,634,810	11,119,444	11,004,831	10,397,140
Unvested Restricted Common Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	49,457	4,891	16,667	152,808

Business Segment, Geographic,_3

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Dec. 31, 2019ft²	Sep. 30, 2019Segment
Segment Reporting Information [Line Items]
Number of operating segments		3
Number of square foot facility produce validation batches | ft²	440,000
Segments Deriving Revenue
Segment Reporting Information [Line Items]
Number of reportable segments		2

Business Segment, Geographic,_4

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue:
Total consolidated revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
Operating Segments
Total revenue:
Total consolidated revenue	20,090	19,524	69,414	71,529
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	115	5,117	421	30,532
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue	7,969	7,092	30,714	17,991
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue	12,006	7,315	38,279	23,006
Intersegment Eliminations
Total revenue:
Total consolidated revenue	$ (726)	$ (1,096)	$ (2,546)	$ (3,700)

Business Segment, Geographic,_5

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue by product group:
Total consolidated revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
API Sales
Total revenue by product group:
Total consolidated revenue	3,647	3,690	12,308	9,538
Medical Device Sales
Total revenue by product group:
Total consolidated revenue		1,322		2,342
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	93	17	382	412
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	15,497	8,280	53,743	25,092
License Fees
Total revenue by product group:
Total consolidated revenue		5,000		30,000
Other Revenue
Total revenue by product group:
Total consolidated revenue	$ 127	$ 119	$ 435	$ 445

Business Segment, Geographic,_6

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (34,758)	$ (46,170)	$ (102,022)	$ (90,327)
Oncology Innovation Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(29,732)	(37,638)	(87,127)	(65,985)
Global Supply Chain Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(3,376)	(6,089)	(3,829)	(16,780)
Commercial Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (1,650)	$ (2,443)	$ (11,066)	$ (7,562)

Business Segment, Geographic,_7

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Total depreciation and amortization:
Total consolidated depreciation and amortization	$ 1,001	$ 909	$ 2,808	$ 2,424
Total assets:
Total consolidated assets	287,595		287,595		$ 231,095
Oncology Innovation Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	227	174	626	505
Total assets:
Total consolidated assets	174,938		174,938		135,878
Global Supply Chain Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	376	490	1,012	1,185
Total assets:
Total consolidated assets	65,833		65,833		58,816
Commercial Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	398	$ 245	1,170	$ 734
Total assets:
Total consolidated assets	$ 46,824		$ 46,824		$ 36,401

Business Segment, Geographic,_8

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue:
Total consolidated revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
United States
Total revenue:
Total consolidated revenue	15,624	9,559	54,119	27,405
Spain
Total revenue:
Total consolidated revenue		5,000		30,000
India
Total revenue:
Total consolidated revenue	1,684	259	3,066	1,701
South Korea
Total revenue:
Total consolidated revenue	513		513
Austria
Total revenue:
Total consolidated revenue	476	2,227	4,423	5,102
China
Total revenue:
Total consolidated revenue	563	306	1,837	1,917
Germany
Total revenue:
Total consolidated revenue	398		602
United Kingdom
Total revenue:
Total consolidated revenue			1,023
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 106	$ 1,077	$ 1,285	$ 1,704

Business Segment, Geographic,_9

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Total property and equipment, net:
Total consolidated property and equipment, net	$ 19,272	$ 11,447
United States
Total property and equipment, net:
Total consolidated property and equipment, net	10,791	6,549
China
Total property and equipment, net:
Total consolidated property and equipment, net	$ 8,481	$ 4,898

Business Segment, Geographic_10

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Detail) - Commercial Platform and Global Supply Chain - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	12.00%	20.00%	13.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	22.00%	11.00%	17.00%	8.00%
Customer Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	13.00%	16.00%	9.00%
Customer Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage		27.00%		44.00%
Customer Revenue | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage	2.00%	10.00%	6.00%	6.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			40.00%		16.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage			35.00%		18.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage			10.00%		12.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
Revenue recognition cash discount percentage	2.30%		2.30%
Provision for chargebacks and other deductions total	$ 19,909		$ 19,909		$ 13,101
General settlement period for rebates and fees			Settlement of rebates and fees may generally occur from one to five months from date of sale.
Deferred revenue	20,071		$ 20,071		190
Out-license Revenue
Revenue Recognition Milestone Method [Line Items]
Deferred revenue	20,000		20,000
Commercial Platform
Revenue Recognition Milestone Method [Line Items]
Provision for chargebacks and other deductions total	19,900		19,900		13,100
Chargebacks and other deductions expense	20,400	11,400	59,800	24,300
Oncology Innovation Platform
Revenue Recognition Milestone Method [Line Items]
Revenue to be recognized upon satisfaction of performance obligation	20,000		20,000
Oncology Innovation Platform | Out-license Revenue
Revenue Recognition Milestone Method [Line Items]
Deferred revenue	20,000		20,000
Global Supply Chain Platform
Revenue Recognition Milestone Method [Line Items]
Revenue to be recognized upon satisfaction of performance obligation	100		100
Global Supply Chain Platform | Out-license Revenue
Revenue Recognition Milestone Method [Line Items]
Deferred revenue	100		100		$ 200
Transferred at a Point in Time
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 0	$ 5,000	$ 0	$ 30,000
Type of Revenue [Extensible List]	atnx:LicenseForIntellectualPropertyMember	atnx:LicenseForIntellectualPropertyMember	atnx:LicenseForIntellectualPropertyMember	atnx:LicenseForIntellectualPropertyMember
Transferred at a Point in Time | Commercial Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 12,006	$ 7,315	$ 38,279	$ 23,006
Transferred at a Point in Time | Oncology Innovation Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	115	5,117	421	30,532
Transferred at a Point in Time | Global Supply Chain Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 7,243	$ 5,996	$ 28,168	$ 14,291

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 19,364	$ 18,428	$ 66,868	$ 67,829
Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	0	5,000	0	30,000
Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	115	5,117	421	30,532
Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	7,243	5,996	28,168	14,291
Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	12,006	7,315	38,279	23,006
United States
Disaggregation Of Revenue [Line Items]
Total revenue	15,624	9,559	54,119	27,405
United States | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	3,618	2,244	15,840	4,399
United States | Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	12,006	7,315	38,279	23,006
India
Disaggregation Of Revenue [Line Items]
Total revenue	1,684	259	3,066	1,701
India | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	1,684	259	3,066	1,701
Austria
Disaggregation Of Revenue [Line Items]
Total revenue	476	2,227	4,423	5,102
Austria | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	476	2,227	4,423	5,102
China
Disaggregation Of Revenue [Line Items]
Total revenue	563	306	1,837	1,917
China | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	115	117	421	532
China | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	448	189	1,416	1,385
South Korea
Disaggregation Of Revenue [Line Items]
Total revenue	513		513
South Korea | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	513		513
United Kingdom
Disaggregation Of Revenue [Line Items]
Total revenue			1,023
United Kingdom | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue			1,023
Germany
Disaggregation Of Revenue [Line Items]
Total revenue	398		602
Germany | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	398		602
Spain
Disaggregation Of Revenue [Line Items]
Total revenue		5,000		30,000
Spain | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue		5,000		30,000
Other Foreign Countries
Disaggregation Of Revenue [Line Items]
Total revenue	106	1,077	1,285	1,704
Other Foreign Countries | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	$ 106	$ 1,077	$ 1,285	$ 1,704

Revenue Recognition - Summary o

Revenue Recognition - Summary of Receivables and Contract Liabilities From Contracts with Customers (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Change In Contract With Customer Liability [Abstract]
Accounts receivable, gross	$ 37,210	$ 26,061
Chargebacks and other deductions	(19,909)	(13,101)
Allowance for doubtful accounts	(133)	(9)
Accounts receivable, net	17,168	12,951
Deferred revenue	20,071	190
Total contract liabilities	$ 20,071	$ 190

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Accounts Receivable Balances by Reportable Segments (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	$ 37,210	$ 26,061
Allowance for doubtful accounts, chargebacks, and other deductions	(20,042)	(13,110)
Accounts receivable, net	17,168	12,951
Global Supply Chain Platform
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	4,888	7,814
Allowance for doubtful accounts, chargebacks, and other deductions	(120)	(9)
Accounts receivable, net	4,768	7,805
Commercial Platform
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	32,322	18,247
Allowance for doubtful accounts, chargebacks, and other deductions	(19,922)	(13,101)
Accounts receivable, net	$ 12,400	$ 5,146

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2019	$ 2,943
2020	2,466
2021	2,040
2022	1,902
2023	1,675
Thereafter	3,099
Future minimum payments under non-cancelable leases	$ 14,125